AbbVie Inc.(ABBV)
đ Dividend Highlights
Previous Payout History
50 payouts shown| Pay Date | Amount Per Share | Change vs Previous |
|---|---|---|
| May 15, 2025 | $1.64 | - |
| February 14, 2025 | $1.64 | â˛5.81% |
| November 15, 2024 | $1.55 | - |
| August 15, 2024 | $1.55 | - |
| May 15, 2024 | $1.55 | - |
| February 15, 2024 | $1.55 | â˛4.73% |
| November 15, 2023 | $1.48 | - |
| August 15, 2023 | $1.48 | - |
| May 15, 2023 | $1.48 | - |
| February 15, 2023 | $1.48 | â˛4.96% |
| November 15, 2022 | $1.41 | - |
| August 15, 2022 | $1.41 | - |
| May 16, 2022 | $1.41 | - |
| February 15, 2022 | $1.41 | â˛8.46% |
| November 15, 2021 | $1.30 | - |
| August 16, 2021 | $1.30 | - |
| May 14, 2021 | $1.30 | - |
| February 16, 2021 | $1.30 | â˛10.17% |
| November 16, 2020 | $1.18 | - |
| August 14, 2020 | $1.18 | - |
| May 15, 2020 | $1.18 | - |
| February 14, 2020 | $1.18 | â˛10.28% |
| November 15, 2019 | $1.07 | - |
| August 15, 2019 | $1.07 | - |
| May 15, 2019 | $1.07 | - |
| February 15, 2019 | $1.07 | â˛11.46% |
| November 15, 2018 | $0.96 | - |
| August 15, 2018 | $0.96 | - |
| May 15, 2018 | $0.96 | â˛35.21% |
| February 15, 2018 | $0.71 | â˛10.94% |
| November 15, 2017 | $0.64 | - |
| August 15, 2017 | $0.64 | - |
| May 15, 2017 | $0.64 | - |
| February 15, 2017 | $0.64 | â˛12.28% |
| November 15, 2016 | $0.57 | - |
| August 15, 2016 | $0.57 | - |
| May 16, 2016 | $0.57 | - |
| February 16, 2016 | $0.57 | â˛11.76% |
| November 14, 2015 | $0.51 | - |
| August 14, 2015 | $0.51 | - |
| May 15, 2015 | $0.51 | â˛4.08% |
| February 13, 2015 | $0.49 | â˛16.67% |
| November 17, 2014 | $0.42 | - |
| August 15, 2014 | $0.42 | - |
| May 15, 2014 | $0.42 | â˛5.00% |
| February 14, 2014 | $0.40 | - |
| November 15, 2013 | $0.40 | - |
| August 15, 2013 | $0.40 | - |
| May 15, 2013 | $0.40 | - |
| February 15, 2013 | $0.40 |
Overall Dividend Trend
Dividend per share has changed by+310.00%over the past 12years(comparing first and last payout shown).
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company that focuses on developing innovative therapies for some of the world's most challenging health conditions. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie has quickly established itself in the pharmaceutical industry. The company is headquartered in North Chicago, Illinois. As of the latest update, AbbVie's CEO is Richard A. Gonzalez, who has been instrumental in guiding the company to significant growth and development. In 2022, AbbVie reported annual revenues of approximately $58 billion, driven by its strong portfolio of products, including the widely known immunology drug Humira and cancer treatment Imbruvica. AbbVie is committed to research and development, investing heavily in creating solutions for chronic diseases like immunology, oncology, neuroscience, and ophthalmology. Their innovative approach aims to improve the lives of patients worldwide, making AbbVie a key player in the global healthcare sector.
Abbott Laboratories(ABT)
Amgen Inc.(AMGN)
Bristol-Myers Squibb Company(BMY)
Eli Lilly and Company(LLY)
Gilead Sciences, Inc.(GILD)
Johnson & Johnson(JNJ)
Merck & Co., Inc.(MRK)
Moderna, Inc.(MRNA)
Pfizer Inc.(PFE)Dividend data last updated:Tue, 20 May 2025 05:57:46 GMT. Financial data is indicative and provided for informational purposes only.